Literature DB >> 18698234

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.

Monika Bialecka1, Mateusz Kurzawski, Gabriela Klodowska-Duda, Grzegorz Opala, Eng-King Tan, Marek Drozdzik.   

Abstract

INTRODUCTION: Differences in catechol-O-methyltransferase (COMT) activity and genotype may determine individual variations in the therapeutic response to levodopa or Parkinson's disease (PD) susceptibility. The role of functional COMT haplotypes in PD susceptibility and treatment response has not been examined.
OBJECTIVES: In this case-control study, we investigated the association of the most common COMT gene haplotypes (formed by single nucleotide polymorphisms (SNPs): rs6269:A>G; rs4633C>T; rs4818:C>G; and rs4680:A>G) with PD risk and the association of the COMT haplotypes with the dose and complications of levodopa therapy in PD patients.
METHODS: A total of 679 study participants (322 PD and 357 controls) were included. Each participant was genotyped for four SNPs in the COMT gene, located in a common haploblock, that has been shown to influence COMT enzymatic activity. The influence of COMT haplotypes on the dose of levodopa administered during fifth year of treatment, and occurrence of motor complications were examined in PD patients. The EH program (Jurg Ott, Rockefeller University, New York, USA) was used to estimate haplotype frequencies.
RESULTS: The estimated frequencies of low (A_C_C_G) and medium (A_T_C_A) activity haplotypes tended to be slightly lower among PD patients when compared with controls (P=0.09, G_C_G_G-high activity haplotype as reference). The frequency of G_C_G_G (high activity) haplotype carriers was higher in late onset PD patients (P=0.04) compared with controls. The mean levodopa dose increased with the activity of the functional haplotypes (low<medium<high). Doses prescribed for G_C_G_G (high activity) haplotype carriers (mean 604.2+/-261.9 mg) were significantly higher than those for the noncarriers (mean 512.2+/-133.5 mg, P<0.05). The COMT haplotype seemed to have little influence on the development of levodopa-induced dyskinesias.
CONCLUSION: Our study showed a possible association of functional COMT haplotypes with the risk of PD. Both nonsynonymous and synonymous SNPs within functional COMT haplotype blocks may be more relevant than individual SNPs in conferring PD susceptibility. The doses of levodopa treatment can be influenced by specific COMT haplotypes and this may be useful in instituting individualized therapy for PD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698234     DOI: 10.1097/FPC.0b013e328306c2f2

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  24 in total

1.  Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.

Authors:  Oscar Solís; Jose-Rubén García-Montes; Patricia Garcia-Sanz; Antonio S Herranz; Maria-José Asensio; Gina Kang; Noboru Hiroi; Rosario Moratalla
Journal:  Neurobiol Dis       Date:  2017-03-16       Impact factor: 5.996

2.  IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.

Authors:  Talene A Yacoubian
Journal:  Neurodegener Dis Manag       Date:  2013-04-01

Review 3.  Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

Authors:  Cristina Politi; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Neuromolecular Med       Date:  2018-01-05       Impact factor: 3.843

Review 4.  Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.

Authors:  Sara Bandres-Ciga; Monica Diez-Fairen; Jonggeol Jeff Kim; Andrew B Singleton
Journal:  Neurobiol Dis       Date:  2020-01-25       Impact factor: 5.996

Review 5.  Between destiny and disease: genetics and molecular pathways of human central nervous system aging.

Authors:  Christin Glorioso; Etienne Sibille
Journal:  Prog Neurobiol       Date:  2010-12-02       Impact factor: 11.685

6.  Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.

Authors:  Caroline Moreau; Sayah Meguig; Jean-Christophe Corvol; Julien Labreuche; Francis Vasseur; Alain Duhamel; Arnaud Delval; Thomas Bardyn; Jean-Christophe Devedjian; Nathalie Rouaix; Gregory Petyt; Christine Brefel-Courbon; Fabienne Ory-Magne; Dominique Guehl; Alexandre Eusebio; Valérie Fraix; Pierre-Jean Saulnier; Ouhaid Lagha-Boukbiza; Frank Durif; Mirela Faighel; Caroline Giordana; Sophie Drapier; David Maltête; Christine Tranchant; Jean-Luc Houeto; Bettina Debû; Jean-Philippe Azulay; François Tison; Alain Destée; Marie Vidailhet; Olivier Rascol; Kathy Dujardin; Luc Defebvre; Régis Bordet; Bernard Sablonnière; David Devos
Journal:  Brain       Date:  2015-03-23       Impact factor: 13.501

Review 7.  Genes, cognition and brain through a COMT lens.

Authors:  D Dickinson; B Elvevåg
Journal:  Neuroscience       Date:  2009-05-13       Impact factor: 3.590

8.  Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson's Disease, and Levodopa Efficacy.

Authors:  Bowen Yin; Yongqian Chen; Limei Zhang
Journal:  Mol Diagn Ther       Date:  2013-11-15       Impact factor: 4.074

9.  Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease.

Authors:  Kathryn T Hall; Christopher P Nelson; Roger B Davis; Julie E Buring; Irving Kirsch; Murray A Mittleman; Joseph Loscalzo; Nilesh J Samani; Paul M Ridker; Ted J Kaptchuk; Daniel I Chasman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-07-17       Impact factor: 8.311

Review 10.  Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.

Authors:  Yanying Yin; Yang Liu; Meisong Xu; XiaoMin Zhang; Chen Li
Journal:  Neurol Sci       Date:  2021-08-04       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.